ArriVent BioPharma (AVBP) shares plummeted over 50% after its Phase 3 FURVENT trial for firmonertinib missed its primary endpoint. SueWallSt, represented by Levi & Korsinsky LLP, has launched an investigation into potential securities law violations regarding misleading statements about the trial's prospects. Investors who suffered losses are encouraged to submit their information for a review of potential recovery claims.